AMRN Q1 Vascepa revenue down year over year
$AMRN reports Q1 product revenue of $141.3M - down 3% YoY; Generic $HKMPY took 9% of prescriptions; #Vaskepa Launching in Germany in Q3; General Counsel retiring.
See our Vascepa IQ card for more details.
#Vascepa #AMRN
11 Views
Glad to see that stock was not punished today on revenue down YoY and generic already taking 9%. Was retirement of GC expedited by ANDA litigation loss? Looking forward to European launch/revenue later this year.